Pimavanserin 34 mg + Pimavanserin 20 mg
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Agitation and Aggression in Alzheimer's Disease
Conditions
Agitation and Aggression in Alzheimer's Disease
Trial Timeline
Nov 1, 2016 → Feb 16, 2018
NCT ID
NCT02992132About Pimavanserin 34 mg + Pimavanserin 20 mg
Pimavanserin 34 mg + Pimavanserin 20 mg is a phase 2 stage product being developed by Acadia Pharmaceuticals for Agitation and Aggression in Alzheimer's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT02992132. Target conditions include Agitation and Aggression in Alzheimer's Disease.
What happened to similar drugs?
2 of 14 similar drugs in Agitation and Aggression in Alzheimer's Disease were approved
Approved (2) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
12
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02992132 | Phase 2 | Terminated |
Competing Products
20 competing products in Agitation and Aggression in Alzheimer's Disease